Turning radiotherapy into an effective systemic anti-cancer treatment in combination with immunotherapy

Clinical Oncology

Volumn 27, Issue 12, 2015, Pages 696-699

  Illidge, T ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMMUNOMODULATING AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; HEAD AND NECK CANCER; HUMAN; IMMUNOSTIMULATION; KIDNEY CANCER; METASTATIC MELANOMA; NEOPLASM; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; RADIOTHERAPY; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 84960478766     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2015.09.001     Document Type: Editorial

References (18)

1. Lee Y., Auh S.L., Wang Y., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
2. Lugade A.A., Moran J.P., Gerber S.A., Rose R.C., Frelinger J.G., Lord E.M. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174:7516-7523.
3. Apetoh L., Ghiringhelli F., Tesniere A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
4. Gardai S.J., McPhillips K.A., Frasch S.C., et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123:321-334.
5. Reynders K., Illidge T., Siva S., Chang J.Y., De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 2015, 41(6):503-510.
6. Honeychurch J., Cheadle E.J., Dovedi S.J., Illidge T.M. Immuno-regulatory antibodies for the treatment of cancer. Expert Opin Biol Ther 2015, 15(6):787-801.
7. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010, 363(8):711.
8. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
9. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
10. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
11. Sznol M., Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013, 19:1021-1034.
12. Teng F., Kong L., Meng X., Yang J., Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. Cancer Lett 2015, 365(1):23-29.
13. Postow M.A., Callahan M.K., Barker C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366(10):925-931.
14. Slovin S.F., Higano C.S., Hamid O., et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013, 24(7):1813-1821.
15. Grimaldi A.M., Simeone E., Giannarelli D., et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014, 3:e28780.
16. Deng L., Liang H., Burnette B., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014, 124(2):687-695.
17. Dovedi S.J., Adlard A.L., Lipowska-Bhalla G., et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014, 74(19):5458-5468.
18. Twyman-Saint Victor C., Rech A.J., Maity A., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520(7547):373-377.